Plasma-Based Genotyping in Advanced Solid Tumors: A Comprehensive Review
Molecular genotyping for advanced solid malignancies has transformed the clinical management of patients with metastatic disease. Treatment decisions in a growing number of tumors require knowledge of molecularly driven alterations in order to select optimal targeted therapy. Although genomic testin...
Guardado en:
Autores principales: | Maisam Makarem, Miguel García-Pardo, Natasha B. Leighl |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8efdeb04dad94efea67c4b5508660793 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer
por: Veldore VH, et al.
Publicado: (2018) -
Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors
por: Lionel Larribère, et al.
Publicado: (2021) -
Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers
por: Hitomi Sumiyoshi Okuma, et al.
Publicado: (2021) -
Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact
por: Natasha Honoré, et al.
Publicado: (2021) -
Case Report: The Added Value of Liquid Biopsy in Advanced Colorectal Cancer From Clinical Case Experiences
por: Paola Ulivi, et al.
Publicado: (2021)